Continuous glucose monitoring in people with type 2 diabetes undergoing cardiac surgery - a cohort trial

Continuous glucose monitoring in people with type 2 diabetes undergoing cardiac surgery - a cohort trial - CCS-1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031915

Enrollment

160

Registered

2023-06-01

Start date

2023-06-29

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11

Interventions

Group 1: People with type 2 diabetes undergoing cardiac surgery: This prospective cohort study will include three study visits, two of which will be performed at the Department for Cardiac Surgery at

Eligibility

Sex/Gender

All

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: a) People with type 2 diabetes either on dietary control or on glucose lowering treatment including any oral glucose lowering drugs or GLP1-receptor agonists b) Admitted to hospital for cardiac surgery (coronary artery bypass surgery or valve replacement) c) Age 50-80 years (both inclusive) d) Written informed consent

Exclusion criteria

Exclusion criteria: a) Type 1 diabetes b) Pre-existing insulin treatment c) Insulin pump treatment d) Glucocorticoid treatment e) End stage renal disease f) Severe liver impairment g) Any mental condition rendering the patient incapable of giving informed consent h) Participation in another trial which might interfere with the procedures of this trial

Design outcomes

Primary

Measure	Time frame
Composite of postsurgical complications (including surgical site infection, pneumonia, ICU readmission, acute renal failure, re-hospitalisations). Endpoint definition: Surgical Site infection: an infection related to a surgical procedure that occurs near the surgical site within 30 days following surgery. Acute kidney injury: (according to KDIGO, Kidney Int 2012) AKI is defined as any of the following: 1) Increase in sCr =0.3 mg/dL within 48 hours 2) Increase in sCr =1.5 times baseline (visit 1) 3) Urine volume =38.5°C 2) blood leucocyte count >10.000/µL or < 4.000/µL 3) purulent secretion 4) confirmed bacterial or viral infection 5) signs of pneumonia after physical examination	—

Measure

Time frame

Composite of postsurgical complications (including surgical site infection, pneumonia, ICU readmission, acute renal failure, re-hospitalisations). Endpoint definition: Surgical Site infection: an infection related to a surgical procedure that occurs near the surgical site within 30 days following surgery. Acute kidney injury: (according to KDIGO, Kidney Int 2012) AKI is defined as any of the following: 1) Increase in sCr =0.3 mg/dL within 48 hours 2) Increase in sCr =1.5 times baseline (visit 1) 3) Urine volume =38.5°C 2) blood leucocyte count >10.000/µL or < 4.000/µL 3) purulent secretion 4) confirmed bacterial or viral infection 5) signs of pneumonia after physical examination

—

Secondary

Measure	Time frame
a) Composite of postsurgical complications during the index hospital stay only b) Incidence Surgical site infections (CDC definition) c) Length of hospital stay d) Length of ICU stay e) 180-day mortality f) Acute kidney injuries g) Number of re-hospitalisations after discharge h) Hospitalisations for cardiovascular causes (including myocardial infarction, stroke, hospitalisation for heart failure, hospitalisation for revascularisation procedure) i) Number of fatal events j) Glycaemic parameters including TIR, TTR, TARI, TBR1, TAR2, TBR, mean glucose and glucose variability	—

Measure

Time frame

a) Composite of postsurgical complications during the index hospital stay only b) Incidence Surgical site infections (CDC definition) c) Length of hospital stay d) Length of ICU stay e) 180-day mortality f) Acute kidney injuries g) Number of re-hospitalisations after discharge h) Hospitalisations for cardiovascular causes (including myocardial infarction, stroke, hospitalisation for heart failure, hospitalisation for revascularisation procedure) i) Number of fatal events j) Glycaemic parameters including TIR, TTR, TARI, TBR1, TAR2, TBR, mean glucose and glucose variability

—

Countries

Austria

Contacts

Public ContactHarald Sourij

Medizinische Universität Graz / Abteilung für Endokrinologie und Diabetologie

ha.sourij@medunigraz.at004331638581310

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026